Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Balanced ETA/ETB antagonist from Abbott

April 22, 1997

Merck KGaA prepares cardioprotective agents

April 22, 1997

PGE1 derivatives for peripheral circulatory disorders from Ono

April 22, 1997

Teva receives FDA approval for antihypertensive generic

April 22, 1997

NitroMed and Cordis collaborate to develop novel cardiovascular products

April 18, 1997

Biovail's Tiazac approved and introduced in Canada

April 17, 1997

Celgene reports dual TNF/PDE inhibitors

April 17, 1997

Defibrillators associated with reduced mortality compared to antiarrhythmic drugs

April 17, 1997

Potent and selective ETA antagonist from SKB

April 16, 1997

CVT-124 enters phase II trials for CHF

April 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...